Found: 7
Select item for more details and to access through your institution.
Correction to: Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.
- Published in:
- Current Oncology Reports, 2020, v. 22, n. 2, p. 1, doi. 10.1007/s11912-020-0877-0
- By:
- Publication type:
- Article
CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response.
- Published in:
- 2018
- By:
- Publication type:
- Letter
PDTM-29. CSF H3F3A K27M CIRCULATING TUMOR DNA COPY NUMBER QUANTIFIES TUMOR GROWTH AND TREATMENT RESPONSE.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi209, doi. 10.1093/neuonc/noy148.870
- By:
- Publication type:
- Article
Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-84513-1
- By:
- Publication type:
- Article
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 8, p. 1366, doi. 10.1093/neuonc/noac030
- By:
- Publication type:
- Article